Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool

• DOI: 10.1371/journal.pone.0046091
• Publication Date: 2012-10-03T21:11:05Z
• Authors: Rachel M. Ostroff; Michael R. Mehan; Alex Stewart; Deborah Ayers; Edward N. Brody; Stephen A. Williams; Stephen Levin; Brad Black; Michael Harbut; Michele Carbone; Chandra Goparaju; Harvey I. Pass
• Keywords: Adult; Male; Mesothelioma; Proteomics; Science; Pleural Neoplasms; Enzyme-Linked Immunosorbent Assay; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Lectins; Biomarkers, Tumor; Humans; Public Health Surveillance; Aged; Aged, 80 and over; Principal Component Analysis; Q; R; Reproducibility of Results; Asbestos; Middle Aged; 3. Good health; Case-Control Studies; Carcinogens; Medicine; Female; Research Article

Malignant pleural mesothelioma (MM) is an aggressive, asbestos-related pulmonary cancer that is increasing in incidence. Because diagnosis is difficult and the disease is relatively rare, most patients present at a clinically advanced stage where possibility of cure is minimal. To improve surveillance and detection of MM in the high-risk population, we completed a series of clinical studies to develop a noninvasive test for early detection.We conducted multi-center case-control studies in serum from 117 MM cases and 142 asbestos-exposed control individuals. Biomarker discovery, verification, and validation were performed using SOMAmer proteomic technology, which simultaneously measures over 1000 proteins in unfractionated biologic samples. Using univariate and multivariate approaches we discovered 64 candidate protein biomarkers and derived a 13-marker random forest classifier with an AUC of 0.99±0.01 in training, 0.98±0.04 in independent blinded verification and 0.95±0.04 in blinded validation studies. Sensitivity and specificity at our pre-specified decision threshold were 97%/92% in training and 90%/95% in blinded verification. This classifier accuracy was maintained in a second blinded validation set with a sensitivity/specificity of 90%/89% and combined accuracy of 92%. Sensitivity correlated with pathologic stage; 77% of Stage I, 93% of Stage II, 96% of Stage III and 96% of Stage IV cases were detected. An alternative decision threshold in the validation study yielding 98% specificity would still detect 60% of MM cases. In a paired sample set the classifier AUC of 0.99 and 91%/94% sensitivity/specificity was superior to that of mesothelin with an AUC of 0.82 and 66%/88% sensitivity/specificity. The candidate biomarker panel consists of both inflammatory and proliferative proteins, processes strongly associated with asbestos-induced malignancy.The SOMAmer biomarker panel discovered and validated in these studies provides a solid foundation for surveillance and diagnosis of MM in those at highest risk for this disease.